Our in vitro data suggested that expression of mutant IRF8 in B cell lymphomas deregulates antigen processing/loading and ultimately presentation in an MHCII context thus eliciting a subpar CD4 response. Here, IRF8 is linked to B-cell non-Hodgkin lymphoma.